BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys.
Authors: Deborah S. Hasin, Melanie Wall, Katherine M. Keyes, Magdalena Cerdá, John Schulenberg, et al
The Lancet Psychiatry, July 2015
—
BACKGROUND: Adolescent use of marijuana is associated with adverse later effects, so the identification of factors underlying adolescent use is of substantial public health importance. The relationship between US state laws that permit marijuana for medical purposes and adoles…
Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors.
Authors: Sania Shakoor, Helena M.S. Zavos, Philip McGuire, Alastair G. Cardno, et al
Psychiatry Research, 30 June 2015
—
Cannabis users are more likely to have psychotic experiences (PEs). The degree to which these associations are driven by genetic or environmental influences in adolescence is unknown. This study estimated the genetic and environmental contributions to the relationship between…
Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.
Authors: Ryan Vandrey, Jeffrey C. Raber, Mark E. Raber, Brad Douglass, Cameron Miller, Marcel O. Bonn-Miller
JAMA, 23 June 2015
—
As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16% to 26% of patients using medical cannabis consume edible products.1,2 Even though oral consumption lacks the harmful by-…
Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.
Authors: Kevin P. Hill
JAMA, 23 June 2015
—
IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and law…
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Authors: Penny F. Whiting, Robert F. Wolff, Sohan Deshpande, Marcello Di Nisio, Steven Duffy, et al
JAMA, 23 June 2015
—
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty…
Medical Marijuana: Is the Cart Before the Horse?
Authors: Deepak Cyril D’Souza, Mohini Ranganathan
JAMA, 23 June 2015
—
There is a pressing need to develop new medications for many debilitating conditions. Novel approaches based on marijuana or its constituent cannabinoids, if proven, could be added to the armamentarium of available treatments. In this issue of JAMA, reviews by Whiting et al1 a…
Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.
Authors: Guy A. Cabral, Thomas J. Rogers, Aron H. Lichtman
Journal of Neuroimmune Pharmacology, June 2015
—
Cannabis is a complex substance that harbors terpenoid-like compounds referred to as phytocannabinoids. The major psychoactive phytocannabinoid found in cannabis ∆(9)-tetrahydrocannabinol (THC) produces the majority of its pharmacological effects through two cannabinoid recep…
Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.
Authors: Rebecca L. Hartman, Timothy L. Brown, Gary Milavetz, Andrew Spurgin, et al
Clinical Chemistry, June 2015
—
BACKGROUND: Increased medical and legal cannabis intake is accompanied by greater use of cannabis vaporization and more cases of driving under the influence of cannabis. Although simultaneous Δ(9)-tetrahydrocannabinol (THC) and alcohol use is frequent, potential pharmacokineti…
Use of cannabis in severe childhood epilepsy and child protection considerations.
Authors: Megan Yap, Laura Easterbrook, Jan Connors, Laura Koopmans
Journal of Paediatrics and Child Health, May 2015
—
The use of medical cannabis in chronic illness is increasingly investigated, yet little is known about its use in paediatric populations. As child protection clinicians are often asked to provide advice around whether parents’ actions to give medical cannabis to their chronica…
Use of Prescription Pain Medications Among Medical Cannabis Patients
Authors: Brian E. Perron, Kipling Bohnert, Angela K. Perone, Marcel O. Bonn-Miller, Mark Ilgen
Journal of Studies on Alcohol and Drugs, May 2015
—
OBJECTIVE: Management of chronic pain is one of the most common reasons given by individuals seeking medical cannabis. However, very little information exists about the concurrent use of cannabis and prescription pain medication (PPM). This study fills this gap in knowledge by…
Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.
Authors: Dimah Saade, Charuta Joshi
Pediatric Neurology, May 2015
—
BACKGROUND: Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalog…
Research Pioneer: Ethan Russo MD
Ethan Russo, MD, is a board-certified neurologist and psychopharmacology researcher. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines.